Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
“The development of life-changing treatments requires that basic science discoveries be actively and aggressively pursued toward clinical testing,” said Katie Hood, CEO of The Michael J. Fox Foundation. “MJFF targets its resources to keep scientific solutions for PD moving toward pharmacy shelves as quickly and efficiently as possible.
Years of basic research in cell-based studies and animal models have uncovered numerous promising biological targets that show initial promise to impact the symptoms and progression of Parkinson’s disease. But translating these fundamental discoveries into practical treatments requires focused and concerted effort to identify and optimize realistic strategies for eventual human testing.
For this new round of
“The Foundation recognizes the strengths beyond target identification that academic scientists bring to therapeutics discovery and development,” said Dr.
Under the 2008
The first two rounds of